98%
921
2 minutes
20
Background And Objectives: Recent technological advances in interventional EUS have improved EUS-guided drainage/anastomosis (EUS-D/A), yet challenges remain. This study evaluated the safety and feasibility of a square flare fully covered self-expandable metallic stent (SF-FCSEMS) with anti-migration properties for EUS-D/A.
Methods: This retrospective cohort study was performed at 2 academic centers and analyzed patients who underwent SF-FCSEMS placement for EUS-D/A from April 2015 to November 2022. We have used an SF-FCSEMS that has a square flare at both ends that is 4 mm larger in diameter than the stent body, providing an anti-migration effect.
Results: Thirty-six patients (median age: 74 years), 41.6% male, were included. Malignancies accounted for 83.3%. Among the EUS-D/A procedure types, EUS-abscess drainage was performed in 52.8%, EUS-guided gallbladder drainage in 30.6%, and EUS-guided abscess drainage in 16.7%. The technical success rate was 97.2%, and the clinical success rate was 97.1%. The median procedure time was 36 minutes, with puncture tract dilation conducted in all cases. Adverse events occurred in 11.1%; recurrent symptoms were observed in 11.8%, with no migration. SF-FCSEMS removal was performed in 26.5% of patients during the follow-up period, with a median duration of 154 days. The total cost of deploying SF-FCSEMS was approximately 40% less than that of using lumen apposing metal stent.
Conclusions: EUS-D/A with an SF-FCSEMS, which has anti-migration properties, not only was effective and feasible in the present study but also demonstrated a cost advantage.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11939935 | PMC |
http://dx.doi.org/10.1097/eus.0000000000000099 | DOI Listing |
Innovation (Camb)
August 2025
Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai 200040, China.
This phase 3 trial evaluated the efficacy and safety of Firsekibart, a novel, fully human anti-interleukin-1β monoclonal antibody, in patients with frequent acute gout flares unsuitable for standard therapy. Patients were randomized (1:1, stratified by baseline pain visual analog scale [VAS]) to the Firsekibart (200 mg) or compound betamethasone (CB; 7 mg) group. Co-primary endpoints included change in pain intensity in the target joint at 72 h (non-inferiority testing) and time to first new flare within 12 weeks (superiority testing).
View Article and Find Full Text PDFJ Clin Med
June 2025
Department of Gastroenterology, Trakya University School of Medicine, 22130 Edirne, Turkey.
: Patients with inflammatory bowel disease (IBD) experience disproportionately high rates of anxiety and depressive symptoms, representing a 2-3-fold increased risk versus the general population. While psychological morbidity is well-documented, the relative contributions of disease activity (active vs. inactive), IBD subtype (ulcerative colitis [UC] vs.
View Article and Find Full Text PDFLancet Rheumatol
August 2025
Medical Technology Research Centre, Anglia Ruskin University, Chelmsford, UK.
Background: Sarilumab is approved for adult patients with polymyalgia rheumatica who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. We aimed to evaluate the effect of sarilumab on patient-reported outcomes.
Methods: This phase 3, double-blind, randomised controlled trial was done in 60 centres in 17 countries.
JMA J
April 2025
Department of Cardiology, National Hospital Organization, Yonago Medical Center, Yonago, Japan.
Introduction: The Japanese Society of Gout, Uric, and Nucleic Acid developed the Japanese Guideline for Management of Hyperuricemia and Gout (JGMHG) third edition, which contains seven clinical questions (CQs) and corresponding recommendations. Questionnaire surveys were conducted to clarify how recommendations regarding CQs influence decision-making in clinical practice.
Methods: The surveillances were conducted twice in 2018, just after the publication of JGMHG, and in 2020, 2 years later.
BMC Oral Health
April 2025
Faculty of Dentistry, Department of Endodontics, Istanbul University, Prof. Dr. Cavit Orhan Tütengil Sk. No:4, Süleymaniye, Fatih, İstanbul, 34116, Turkey.
Background: Ni-Ti instruments with varying design features may lead to different levels of postoperative pain, which is a significant clinical concern, particularly in previously asymptomatic teeth. Therefore, the purpose of this randomized clinical trial is to compare postoperative pain following instrumentation with TruNatomy versus ProTaper Next Ni-Ti systems in mandibular molars with asymptomatic apical periodontitis.
Methods: 90 healthy participants were randomly assigned to two groups: TruNatomy (TN) or ProTaper Next (PTN) instruments.